Your browser doesn't support javascript.
loading
Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.
Lasica, Masa; Anderson, Mary A; Boussioutas, Alex; Gregory, Gareth P; Hamad, Nada; Manos, Kate; McKelvie, Penny; Ng, Michael; Campbell, Belinda; Palfreyman, Emma; Salvaris, Ross; Weinkove, Robert; Wight, Joel; Opat, Stephen; Tam, Constantine.
Afiliação
  • Lasica M; Department of Clinical Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Anderson MA; The University of Melbourne, Melbourne, Victoria, Australia.
  • Boussioutas A; Department of Clinical Haematology, Royal Melbourne Hospital and The Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Gregory GP; Division of Blood Cells and Blood Cancer, Walter and Eliza Hall Institute, Melbourne, Victoria, Australia.
  • Hamad N; Department of Gastroenterology, Alfred Health, Melbourne, Victoria, Australia.
  • Manos K; Monash University, Melbourne, Victoria, Australia.
  • McKelvie P; The Alfred, Melbourne, Victoria, Australia.
  • Ng M; Familial Cancer Clinic, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Campbell B; Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.
  • Palfreyman E; Monash Haematology, Monash Health, Melbourne, Victoria, Australia.
  • Salvaris R; Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
  • Weinkove R; Department of Haematology, Flinders Medical Centre, Adelaide, South Australia, Australia.
  • Wight J; Department of Anatomical Pathology, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Opat S; GenesisCare St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Tam C; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Intern Med J ; 54(6): 1017-1030, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38881453
ABSTRACT
Marginal zone lymphomas (MZLs) are a rare, indolent group of non-Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa-associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence-based recommendations in the setting of Australia and New Zealand.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Zona Marginal Tipo Células B Limite: Humans País/Região como assunto: Oceania Idioma: En Revista: Intern Med J Assunto da revista: MEDICINA INTERNA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Zona Marginal Tipo Células B Limite: Humans País/Região como assunto: Oceania Idioma: En Revista: Intern Med J Assunto da revista: MEDICINA INTERNA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália